Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.
Anilides
/ administration & dosage
Antibodies, Monoclonal, Humanized
/ therapeutic use
Carcinoma, Hepatocellular
/ mortality
Chemoembolization, Therapeutic
Clinical Trials as Topic
Humans
Immunotherapy
/ methods
Liver Neoplasms
/ mortality
Molecular Targeted Therapy
/ methods
Mutation
Phenylurea Compounds
/ therapeutic use
Protein Kinase Inhibitors
/ therapeutic use
Pyridines
/ administration & dosage
Quinolines
/ therapeutic use
beta Catenin
/ genetics
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
received:
26
03
2019
revised:
03
05
2019
accepted:
01
07
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
17
6
2020
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.
Identifiants
pubmed: 31481419
pii: 79/17/4326
doi: 10.1158/0008-5472.CAN-19-0803
pmc: PMC8330805
mid: NIHMS1716346
doi:
Substances chimiques
Anilides
0
Antibodies, Monoclonal, Humanized
0
CTNNB1 protein, human
0
Phenylurea Compounds
0
Protein Kinase Inhibitors
0
Pyridines
0
Quinolines
0
beta Catenin
0
cabozantinib
1C39JW444G
atezolizumab
52CMI0WC3Y
lenvatinib
EE083865G2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4326-4330Subventions
Organisme : NCI NIH HHS
ID : R01 CA233794
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK099558
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC010313
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Lancet Oncol. 2015 Oct;16(13):1344-54
pubmed: 26361969
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Clin Cancer Res. 2019 Apr 1;25(7):2021-2023
pubmed: 30617138
JAMA Oncol. 2018 May 1;4(5):661-669
pubmed: 29543938
J Hepatol. 2018 Mar;68(3):526-549
pubmed: 28989095
Hepatology. 2014 Nov;60(5):1767-75
pubmed: 24839253
Gastroenterology. 2018 Jan;154(1):195-210
pubmed: 28918914
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575
pubmed: 28648803
Diagn Interv Imaging. 2014 Jul-Aug;95(7-8):689-703
pubmed: 24951349